Abstract Library

#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,

Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,

#1684 An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)

Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Duchateau L

Authors: Duchateau L, Lescrauwaet B, Blot K, Liyanage N, Ray D,

Keywords: SSA, carcinoid, symptoms,

#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: PRO,